

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



Piperoxan hydrochloride

Cat. No.: HY-100850 CAS No.: 135-87-5 Molecular Formula: $C_{14}H_{20}CINO_{2}$ Molecular Weight: 269.77

Target: Adrenergic Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

4°C, sealed storage, away from moisture Storage:

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

H₂O: 50 mg/mL (185.34 mM; Need ultrasonic)

DMSO: $\geq 31 \text{ mg/mL} (114.91 \text{ mM})$

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.7069 mL	18.5343 mL	37.0686 mL
	5 mM	0.7414 mL	3.7069 mL	7.4137 mL
	10 mM	0.3707 mL	1.8534 mL	3.7069 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 25 mg/mL (92.67 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description Piperoxan (Benodaine) hydrochloride is an α₂ adrenoceptor antagonist. Piperoxan hydrochloride is the first-generation antihistamine.

IC₅₀ & Target

adrenoceptor^[1]

In Vitro

When the medulla is superfused with α_2 adrenoceptor antagonist Piperoxane (50 μ M; 5 min) while the pons is with artificial cerebrospinal fluid (ACSF), the three inactive preparations display rhythmic phrenic bursts at a low frequency (2-4 c/min), and the phrenic burst frequency of the 12 active ones significantly increases during the last 3 min of Piperoxane applications (163±12% of the previous mean frequency). In active medullary preparations, the effects of NA applications (25 μM; 5 min) are compared when the preparations sre superfused either by ACSF (n=8) or by the α 2 adrenoceptor antagonist Piperoxane (50 μM; PIP-ACSF; n=5). NA applications either alone (NA-ACSF) or with Piperoxane (PIP-ACSF+NA) significantly increases the phrenic burst frequency. However, the blockage of the medullary α2 adrenoceptors by Piperoxane potentiates a phrenic

burst frequency increase: during the fifth minute of NA applications, the phrenic burst frequency reached 171±11% of the mean control value when ACSF is applied alone and 234±21% of the mean control value when PIP-ACSF is applied in control condition^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay [1]

The mouse neonates (P0-P3) are ether-anesthetized and decerebrated; the brain stems and the cervical spinal cords are dissected out and placed ventral sides up in a 2 mL chamber superfused with artificial cerebrospinal fluid (ACSF) at $27\pm0.25^{\circ}\text{C}$ (mean±SD), renewed at a rate of 2 mL/min. The ACSF [containing (in mM) 129 NaCl, 3.35 KCl, 1.26 CaCl₂, 1.15 MgCl $_2$, 21 NaHCO $_3$, 0.58 NaH $_2$ PO $_4$, and 30 glucose] is oxygenated and equilibrated (pH 7.4 at 27 $^{\circ}\text{C}$) by bubbling carbogene (95% O $_2$ -5% CO $_2$). In the pharmacological experiments, this is replaced by another ACSF in which bioreactive substances are dissolved: noradrenaline at 25 μ M (NA-ACSF) or α 2 adrenoceptor antagonists, either Piperoxane at 50 μ M (PIP-ACSF) or yohimbine at 50 μ M (YO-ACSF). In some of the experiments, a patch-clamp microelectrode (1 μ m diameter tip) is lowered within the ventral pons into the A5 nucleus where a solution of either ACSF or NA (1 mM) is pressure-ejected. The ejected volume is estimated 20 nL for a pressure pulse lasting 2 s^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration [2]

Mice^[2]

Male Balb-C mice are used, weighing between 20 and 25 g. In mice pretreated with the α -adrenoceptor antagonist Piperoxan, or with naloxone, both at a dose of 3×10^{-5} mol /kg s.c. given 15 min before the acetic acid, the antinociceptive action of (-)-isoprenaline is only slightly antagonized. Dose-ratios of 1.45 and 1.7, are produced by these two antagonists. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Viemari JC, et al. Nasal trigeminal inputs release the A5 inhibition received by the respiratory rhythm generator of the mouse neonate. J Neurophysiol. 2004 Feb;91(2):746-58.

[2]. Bentley GA, et al. The antinociceptive action of some beta-adrenoceptor agonists in mice. Br J Pharmacol. 1986 Jul;88(3):515-21.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA